Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8864730 | 0.90 | NPC1 (0.60) | ALDH1A1MAPTLMNANPSR1HPGD | |
| SCHEMBL31255517 | 0.90 | MAPT (0.56) | ALDH1A1MAPTLMNANPSR1HPGD | |
| SCHEMBL8322813 | 0.89 | MAPT (0.56) | ALDH1A1MAPTLMNANPSR1HPGD | |
| SCHEMBL30680765 | 0.88 | MAPT (0.54) | ALDH1A1MAPTLMNANPSR1HPGD | |
| SCHEMBL17066157 | 0.88 | MAPT (0.57) | ALDH1A1MAPTLMNANPSR1HPGD | |
| SCHEMBL31415261 | 0.88 | MAPT (0.57) | ALDH1A1MAPTLMNANPSR1HPGD | |
| SCHEMBL16408222 | 0.88 | MAPT (0.54) | ALDH1A1MAPTLMNANPSR1HPGD | |
| SCHEMBL17937091 | 0.87 | NPSR1 (0.51) | ALDH1A1MAPTLMNANPSR1HPGD | |
| SCHEMBL2325339 | 0.87 | MAPT (0.53) | ALDH1A1MAPTLMNANPSR1HPGD | |
| SCHEMBL12238281 | 0.85 | MAPT (0.61) | ALDH1A1MAPTLMNANPSR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180104364-A1 | TEXAPHYRIN-PHOSPHOLIPID CONJUGATES AND METHODS OF PREPARING SAME | UNIVERSITY HEALTH NETWORK (CA) | 2018-04-19 | — | — | US | disclosed |
| WO-2016165006-A1 | TEXAPHYRIN-PHOSPHOLIPID CONJUGATES AND METHODS OF PREPARING SAME | UNIVERSITY HEALTH NETWORK (CA) | 2016-10-20 | — | — | WO | disclosed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7566789-B2 | Benzimidazole derivatives | MERCK PATENT GMBH (DE) | 2009-07-28 | — | — | US | disclosed |
| US-7566789-B2 | Benzimidazole derivatives | MERCK PATENT GMBH (DE) | 2009-07-28 | — | — | US | disclosed |
| EP-2061768-A2 | IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | Exelixis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008042282-A2 | IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | EXELIXIS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
| EP-1558247-B1 | BENZIMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2004017963-A1 | BENZIMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | ALDH1A1 4295/4885MAPT 2138/4885LMNA 4821/4885 |
| US-20180104364-A1 | TEXAPHYRIN-PHOSPHOLIPID CONJUGATES AND METHODS OF PREPARING SAME | PLTP, PHOSPHO1, TEX13A | ALDH1A1 4042/4885MAPT 4330/4885LMNA 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.